Johnson & Johnson’s multiple myeloma treatment secures EC approval
Pharmaceutical Business Review·RemeGen reports RMB 3.84 billion cash balance as of June 30, 2026 in H1 presentation
PUBT·- RemeGen reported a cash balance of RMB 3.84 billion and domestic drug sales of RMB 1.4 billion for H1 2026. - The company highlighted commercial portfolios like telitacicept and disitamab vedotin, alongside global partnerships with potential value exceeding USD 12 billion. - Key clinical updates included Phase 3 readouts for telitacicept, notably showing a 55% placebo-adjusted 24-hour UPCR reduction in the IgAN study.